EURO BIOPHARMA 2021: AlgoLight, a photobioreactor platform for microalgae-based biopharmaceuticals- Jean François JENCK-ALGOLIGHT

Jean François JENCK

Abstract

Microalgae are explored as a next-generation platform to produce biopharmaceuticals. Compared to current methods (mammalian cells, yeast, techniques bacteria), plant-based have the advantages of higher biosynthetic capacity, genetic engineering flexibility, absence of human pathogens, and finally lower cost. Photosynthetic microalgae have been proven at the lab scale to be a viable option for recombinant protein production, due to successful genes expression. On the way to commercialization, process development is now critical. A process using genetically modified microorganisms must meet the regulatory legislation (UE Directive 2009/41/CE 6 May 2009). The production of microalgae in low-cost open systems can be easily contaminated and cannot avoid the spread of strains into the environment. A containment is possible in closed bioreactors, but the axenic character is not guaranteed, the control of the growth parameters is complex, the poor light distribution (either solar or artificial) is the limiting leading to low productivity. AlgoLight factor (www.algolight.com), cooperation with in the University Nantes, has developed of а photobioreactor with internal volumetric illumination: PRIAM has a very high specific light area (up to 500 m-1), thus making it extremely productive and compact. The technology is based on a multilayer stack of double-sided light-emitting Lightex[®] plates, incorporating woven optical fibers fabrics fed by LEDs. The volumic productivity of a fermenter can now be reached in a photosynthetic process. Opening a way to the cGMP-compliant production of plant based therapeutic proteins in large-scale systems, our

PRIAM photobioreactor is currently being scaled-up into a preindustrial platform.

Bottom Note: This work is partly presented at 7th European Biopharma Congress; Webinar- April 27-28, 2020.

Jean François JENCK ALGOLIGHT, France

7th European Biopharma Congress